1. Home
  2. PMTS vs SAVA Comparison

PMTS vs SAVA Comparison

Compare PMTS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CPI Card Group Inc.

PMTS

CPI Card Group Inc.

HOLD

Current Price

$13.73

Market Cap

183.1M

Sector

Finance

ML Signal

HOLD

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$2.10

Market Cap

156.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMTS
SAVA
Founded
2007
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.1M
156.5M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PMTS
SAVA
Price
$13.73
$2.10
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$32.00
$5.00
AVG Volume (30 Days)
42.3K
1.0M
Earning Date
11-04-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.20
N/A
Revenue
$515,576,000.00
N/A
Revenue This Year
$13.70
N/A
Revenue Next Year
$8.51
N/A
P/E Ratio
$11.53
N/A
Revenue Growth
12.48
N/A
52 Week Low
$11.64
$1.15
52 Week High
$34.25
$4.98

Technical Indicators

Market Signals
Indicator
PMTS
SAVA
Relative Strength Index (RSI) 36.24 36.59
Support Level $13.61 $1.96
Resistance Level $14.83 $2.28
Average True Range (ATR) 0.56 0.15
MACD -0.24 0.01
Stochastic Oscillator 4.26 22.15

Price Performance

Historical Comparison
PMTS
SAVA

About PMTS CPI Card Group Inc.

CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: